This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. ICD-10 code | E84.1 | Special Copayment Reduction: V120 |
| B. Synonyms | Cystic fibrosis with intestinal manifestations, meconium ileus in cystic fibrosis (P75*), distal intestinal obstruction syndrome (DIOS), Mucoviscidosis intestinal form, CF-related exocrine pancreatic insufficiency, CF-related meconium ileus |
| C. Adult onset | Possible first presentation in adulthood — patients with mild CFTR variants may be first diagnosed in adulthood with distal intestinal obstruction syndrome, chronic pancreatitis or malabsorption without a childhood diagnosis |
| 1. History | First described by Andersen in 1938; history of establishing the association between meconium ileus and CF |
| 2. Causes | CFTR gene mutation → excessive viscosity of intestinal mucus → meconium ileus, distal intestinal obstruction syndrome, exocrine pancreatic insufficiency |
| 3. Genetics | Autosomal recessive; CFTR gene; high risk of meconium ileus in ΔF508 homozygotes; modifier genes such as SLC26A9 |
| 4. General epidemiology | Meconium ileus: 10–20% of CF newborns; DIOS: 10–15% of CF patients; exocrine pancreatic insufficiency: about 85% of CF patients |
| 5. Pathophysiology | CFTR deficiency → dehydration of the intestinal mucus layer → increased viscosity → stasis of intestinal contents → bowel obstruction; mucus accumulation in pancreatic ducts → pancreatic damage |
| 6. Symptoms | Neonatal meconium ileus (abdominal distension, vomiting, no passage of meconium), DIOS (right lower quadrant pain, abdominal distension, constipation), steatorrhea, malabsorption, growth retardation |
| 7. Signs | Right lower quadrant mass (ileocecal mass), abdominal distension, tympany, steatorrhea, hypoalbuminemia, fat-soluble vitamin deficiency |
| 8. Screening | Newborn IRT screening; abdominal X-ray; CF screening algorithm for meconium ileus |
| 9. Diagnosis | Meconium ileus: radiologic + surgical findings; DIOS: clinical + imaging; CF confirmation: sweat test + CFTR gene testing |
| 10. Treatment | Meconium ileus: hyperosmolar enema, surgery; DIOS: bowel lavage; pancreatic enzyme replacement; CFTR modulators |
| 11. Prognosis | Good survival after surgery for meconium ileus; overall CF prognosis depends on lung status; appropriate nutritional management is directly linked to lung prognosis |
| 12. Prevention | Reduction of intestinal complications through newborn screening, genetic counseling, preventive bowel management and CFTR modulators |
| 13. References | 10 key references |
Intestinal manifestations of cystic fibrosis have been a core component since the disease was first described. In 1938, Dorothy Hansine Andersen first named this disease, describing in a pediatric autopsy study cases including newborns with meconium ileus along with cystic fibrotic changes of the pancreas. At the time, the name "cystic fibrosis of the pancreas" itself was based mainly on the gastrointestinal phenotype.
In 1945, Farber was the first to systematically describe the mechanism by which meconium ileus occurs in CF. He proposed that increased meconium viscosity due to abnormal composition of glycoproteins in meconium and lack of water causes small bowel obstruction. Thereafter, meconium ileus in children with CF was recognized as the first symptom of the disease and included among the main differential diagnoses of neonatal bowel obstruction.
In the 1960s, it was observed that bowel obstruction arising by a similar mechanism recurs in CF beyond infancy, and this came to be named "Distal Intestinal Obstruction Syndrome (DIOS)", distinguishing it from meconium ileus. DIOS is a complication that is not uncommon even in adult CF patients.
After the discovery of the CFTR gene in 1989, the genetic background of meconium ileus was studied, confirming a high risk of meconium ileus in ΔF508 homozygotes and with combinations of severe CFTR variants. In addition, modifier gene studies showed that SLC26A9 (a chloride–bicarbonate exchanger gene) variants are an additional risk factor for meconium ileus. Since 2019, the triple-combination CFTR modulator (ELX/TEZ/IVA) has been reported to contribute also to normalizing intestinal mucus secretion, reducing the incidence of DIOS and other intestinal complications.
The underlying cause of the intestinal manifestations of CF is loss of CFTR function in intestinal epithelial cells due to pathogenic variants in the CFTR gene. CFTR is expressed on the apical membrane of intestinal epithelial cells throughout the entire intestinal tract and is responsible for Cl⁻ secretion. It is also involved in bicarbonate (HCO₃⁻) secretion and is essential for regulating the pH and viscosity of intestinal mucus.
When CFTR loses function, Cl⁻ and HCO₃⁻ secretion into intestinal secretions decreases, and sodium and water reabsorption increases. As a result, water in the intestinal lumen decreases and the mucus becomes dehydrated, with abnormally increased viscosity. Dehydrated mucus and intestinal contents become entangled and form hardened masses within the intestinal tract. In newborns, meconium undergoes this process and becomes firmly impacted in the terminal ileum, causing bowel obstruction (meconium ileus).
In the pancreas, CFTR mediates HCO₃⁻ and water secretion in pancreatic duct epithelial cells. With loss of CFTR function, the pH within the pancreatic ducts falls and mucus accumulates, obstructing the ducts. Chronic pancreatic duct obstruction leads to destruction of the pancreatic parenchyma by autodigestion and fatty degeneration, resulting in exocrine pancreatic insufficiency (EPI). EPI causes maldigestion and malabsorption of fat, protein and carbohydrate through decreased secretion of digestive enzymes (lipase, protease, amylase).
Risk factors for meconium ileus include the severity of CFTR variants (severe combinations such as ΔF508 homozygosity) and SLC26A9 gene variants. SLC26A9 is an auxiliary channel involved in Cl⁻ secretion in the intestine, and loss of SLC26A9 function on top of CFTR deficiency is presumed to worsen dehydration of intestinal mucus.
The genetic background of the intestinal manifestations of CF is based, like the genetics of CF as a whole (see entry E84.0), on autosomal recessive variants of the CFTR gene. However, the intestinal phenotype, especially whether meconium ileus develops, is determined by the type of CFTR variant and additional modifier genes.
The risk of meconium ileus is high in ΔF508 homozygotes or patients with two severe CFTR variants. Meconium ileus is less frequent with combinations that include mild CFTR variants. As an important modifier gene, polymorphisms of SLC26A9 (11q22.1) (rs7512462, etc.) were confirmed by large-scale genome-wide association studies (GWAS) to independently increase the risk of meconium ileus. KRT18 (keratin 18), MSRA (methionine sulfoxide reductase) and others have been proposed as other modifier genes.
In addition to the severity of CFTR variants, acquired factors such as dehydration, a low-fiber diet, use of opioid analgesics and changes in the gut flora due to antibiotics also play a role in the development of DIOS. DIOS is therefore a complex complication arising from the interaction of genetic vulnerability and environmental factors.
Exocrine pancreatic insufficiency appears almost universally with combinations of severe CFTR variants, whereas pancreatic function is sometimes preserved with mild variants (R117H, etc.). This is called pancreatic sufficient (PS), and these patients generally have better lung function as well.
Meconium ileus occurs in about 10–20% of CF newborns and is one of the most common causes of neonatal bowel obstruction. Conversely, about 90% of newborns with meconium ileus are diagnosed with CF, so meconium ileus is a strong predictor of CF. In the United States, meconium ileus is estimated to occur in about 350–700 CF newborns each year.
Distal intestinal obstruction syndrome (DIOS) occurs in 10–15% of CF patients and is especially common in adult CF patients. DIOS tends to recur, with a high rate of repeated episodes in patients who have had one. Risk factors for DIOS include a history of meconium ileus, dehydration, use of opioid analgesics and neurogenic intestinal dysfunction.
Exocrine pancreatic insufficiency (EPI) appears in about 85–90% of CF patients and is almost universal in patients homozygous for severe CFTR variants. In CF patients with EPI, nutritional deficiency due to fat malabsorption is a chronic process.
CF-related liver disease (CFLD) appears in about 30% of CF patients and can progress to cholestatic cirrhosis due to mucus obstruction of the bile ducts. It is classified under a separate code rather than E84.1 but arises from the mechanism common to intestinal and hepatic lesions.
The core mechanism of the intestinal manifestations of CF is mucus dehydration and increased viscosity due to loss of CFTR function throughout the intestinal tract. In normal intestinal epithelium, CFTR secretes Cl⁻ from the apical membrane into the intestinal lumen, and the resulting osmotic gradient moves water into the lumen so that intestinal contents are adequately hydrated. In addition, pancreatic duct CFTR secretes HCO₃⁻, neutralizing the pH of the duodenal lumen and providing an appropriate environment for activation of pancreatic digestive enzymes.
Mechanism of meconium ileus: in the fetal intestine, loss of CFTR function decreases the secretion of Cl⁻ and water, and glycoprotein-rich meconium becomes dehydrated, forming sticky, hard masses. This abnormal meconium becomes impacted especially in the terminal ileum, causing mechanical bowel obstruction. In complicated meconium ileus, intestinal ischemia, volvulus, perforation, intraperitoneal intestinal cyst formation and peritonitis occur.
Mechanism of distal intestinal obstruction syndrome (DIOS): in the intestine of CF patients, the intestinal contents are chronically dehydrated. When insufficient fluid intake, stopping or insufficient pancreatic enzyme intake, excess high-fiber food, dehydration and the like are added, semisolid intestinal contents accumulate at the ileocecal junction, causing complete or incomplete bowel obstruction. DIOS is a concept distinct from constipation and is defined as accumulation of intestinal contents confined to the ileocecal region.
Mechanism of exocrine pancreatic insufficiency: when CFTR deficiency in the pancreatic ducts decreases HCO₃⁻ and water secretion, the ductal contents become viscous and the ducts become obstructed. Pancreatic duct obstruction causes digestive enzymes to be activated within the pancreas, producing autodigestion, and when this accumulates over a long period, the pancreatic parenchyma becomes atrophic, fibrotic and fatty. Insufficient secretion of digestive enzymes (lipase, protease, amylase) is the direct cause of malabsorption.
Meconium ileus (newborns): in newborns, failure to pass meconium within 24–48 hours after birth is the first abnormal sign. Abdominal distension, vomiting (bilious or nonbilious) and feeding refusal appear. On abdominal palpation, rubbery intestinal contents may be felt in the right lower quadrant. Radiologic findings show distended bowel loops and a characteristic "soap-bubble pattern". In complicated meconium ileus, fever, signs of peritoneal irritation and abdominal rigidity accompany it.
Distal intestinal obstruction syndrome (children and adults): the main symptoms are right lower quadrant pain and cramping, abdominal distension, constipation (no bowel movements), nausea and vomiting. A hard mass is sometimes palpable in the right lower quadrant. Incomplete obstruction is more common than complete obstruction, and differentiation is needed because it is clinically similar to acute appendicitis, intussusception, intestinal tumors and other conditions. Fever is often absent but may appear if complications (intestinal ischemia, perforation) occur.
Symptoms of exocrine pancreatic insufficiency and malabsorption: foul-smelling, greasy fatty stools (steatorrhea), abdominal distension, abdominal pain and excessive flatulence are characteristic. Growth retardation, low weight and muscle wasting are prominent in children. Deficiency of fat-soluble vitamins (A, D, E, K) can cause night blindness, rickets, neurologic abnormalities and a bleeding tendency. Edema due to protein malabsorption may also appear.
Other intestinal symptoms: gastroesophageal reflux (GERD), small intestinal bacterial overgrowth (SIBO), intussusception, rectal prolapse and CF-related liver disease (cholestasis, cirrhosis) may accompany the disease.
Abdominal physical signs: abdominal distension is visible. Percussion reveals tympany, and in severe cases generalized abdominal distension is observed. On palpation, a rubbery fullness or mass is felt in the right lower quadrant. Bowel sounds are hyperactive early in DIOS and decrease with progression. With accompanying peritonitis, rebound tenderness is positive.
Signs of nutritional deficiency: low weight, growth retardation, dry and flaking skin, muscle wasting, edema (hypoalbuminemia) and anemia (iron and folate deficiency) are observed. Vitamin K deficiency may cause a bleeding tendency (gum bleeding, skin bruises), vitamin A deficiency xerophthalmia and vitamin D deficiency findings of rickets.
Laboratory findings: fecal fat testing (72-hour fecal fat measurement or Sudan III staining) confirms steatorrhea. Serum fat-soluble vitamin levels (A, 25-OH D, E, prothrombin time/INR) are reduced. Hypoalbuminemia and hypocholesterolemia reflect nutritional deficiency. Serum amylase and lipase may be low in EPI (reflecting exhaustion of the pancreatic parenchyma). Decreased fecal elastase-1 is a noninvasive diagnostic marker of EPI (normal ≥200 μg/g; <100 μg/g indicates severe EPI).
Imaging findings: plain abdominal X-ray shows distended small bowel gas shadows, air-fluid levels and, in meconium ileus, a characteristic soap-bubble appearance. On abdominal CT, accumulation of fecal intestinal contents in the ileocecal region is the diagnostic finding of DIOS.
Newborn screening (IRT): in newborn screening, measurement of immunoreactive trypsinogen (IRT) targets CF as a whole and is not specific to the intestinal phenotype. Elevated IRT reflects leakage of trypsinogen into the blood due to pancreatic damage. In CF newborns with EPI, IRT tends to be even higher.
CF screening in meconium ileus: if meconium ileus is identified in a newborn, CF is suspected immediately, and sweat testing and CFTR gene testing are performed. In newborns born before newborn screening was in place or missed by screening, CF screening is essential if there is delayed passage of meconium or abdominal distension.
EPI screening: in patients with confirmed CF, growth curve tracking (against standard growth curves), fecal elastase-1 measurement and 72-hour quantitative fecal fat testing are used for EPI screening. Fecal elastase-1 is a relatively simple, noninvasive first-line screening tool. In pediatric CF, EPI screening is recommended at 6 months, at 1 year and annually thereafter.
Screening for intestinal complications in adult CF: in adults with CF who have right lower quadrant pain or chronic constipation, abdominal X-ray or CT is performed to screen for DIOS. Annual liver function tests and abdominal ultrasound are performed to screen for CF-related liver disease.
Diagnosis of meconium ileus: in newborns, a clinical diagnosis is made from clinical symptoms (no passage of meconium, abdominal distension, vomiting) and radiologic findings (soap-bubble pattern or distended small bowel on plain X-ray). Contrast enema (hyperosmolar water-soluble contrast, e.g., Gastrografin) is a method that is both diagnostic and therapeutic. CF is then confirmed by sweat testing and CFTR gene testing.
Diagnosis of DIOS: clinical criteria: symptoms of acute complete or incomplete bowel obstruction in a patient with CF + fecal intestinal contents in the ileocecal region. Abdominal CT: high-density fecal contents (meconium/fecal material) in the ileocecal region, distension of the proximal bowel. DIOS must be differentiated from constipation, appendicitis, intussusception and other causes of bowel obstruction.
Diagnosis of EPI: fecal elastase-1 <200 μg/g (severe <100 μg/g); 72-hour quantitative fecal fat (>7g/day = steatorrhea); measurement of serum fat-soluble vitamins; findings of pancreatic fat deposition and reduced parenchyma on abdominal ultrasound/CT.
Confirmation of CF: CF diagnosis related to intestinal symptoms is made in the same way as for pulmonary CF, by sweat testing (Cl⁻ ≥60 mmol/L) or identification of 2 pathogenic CFTR variants.
Treatment of meconium ileus: (1) Uncomplicated: repeated enemas with hyperosmolar water-soluble contrast (Gastrografin®). The osmotic effect moves water into the intestinal lumen and softens the hard meconium masses. Success rate about 60–75%. Adequate intravenous fluid before and after the enema is essential (to prevent dehydration). (2) Complicated or failed enema: surgery (enterotomy and irrigation, partial bowel resection with anastomosis, Mikulicz enterostomy, etc.). Postoperative stoma care and later reversal surgery are needed. (3) Neonatal intensive care: nasogastric decompression, parenteral nutrition, antibiotics (to prevent peritoneal infection).
Treatment of DIOS: (1) Incomplete obstruction: oral polyethylene glycol (PEG) bowel lavage solution (GoLYTELY®, 2–8 L in divided doses). Oral N-acetylcysteine is also used as an adjunct. (2) Complete obstruction or unable to take oral intake: PEG lavage through a nasogastric tube or hyperosmolar contrast enema. (3) If conservative treatment fails: surgical bowel lavage or partial resection. (4) Prevention: adequate fluid intake, appropriate pancreatic enzyme replacement, adjustment of dietary fiber.
Treatment of exocrine pancreatic insufficiency: (1) Pancreatic Enzyme Replacement Therapy (PERT): high-potency porcine pancreatic enzyme preparations (pancrease, creon, etc.) taken with every meal. 500–2500 U/kg/meal of body weight based on lipase. Dose adjusted until steatorrhea resolves and growth improves. Do not exceed a maximum of 10,000 U/kg/day (risk of fibrosing colonopathy). (2) Fat-soluble vitamin supplementation (A, D, E, K — using CF-specific combination preparations). (3) CFTR modulators (ELX/TEZ/IVA, etc.): restoration of CFTR function normalizes intestinal mucus secretion → improved stool consistency, reduced DIOS frequency and improved digestion and absorption have been reported.
Nutritional therapy: a high-calorie, high-fat diet (120–150% of that of healthy individuals); overnight nasogastric nutritional supplementation is sometimes needed. An individualized dietary plan is developed in collaboration with a dietitian.
Postoperative survival for meconium ileus has now improved greatly to over 95%. Short-term complications (anastomotic leak, short bowel syndrome, sepsis) are the main prognostic factors. CF patients with a history of meconium ileus are reported to have a somewhat higher risk of reduced lung function or recurrent DIOS than CF patients without it, but with current appropriate treatment the difference is gradually narrowing.
DIOS tends to recur, but recurrence can be reduced with appropriate bowel management (adequate fluid intake, optimized PERT, preventive PEG therapy). Only a minority of DIOS cases require surgical intervention.
The overall prognosis of CF is determined mainly by lung function, and the intestinal phenotype itself rarely determines survival. However, because nutritional status is directly linked to lung function, appropriate management of EPI and optimization of nutritional status are important for the long-term lung prognosis. In the era of CFTR modulators, the frequency and severity of intestinal symptoms are decreasing, and partial recovery of pancreatic function has been reported even in patients with EPI.
Progression of CF-related liver disease to portal hypertension, variceal bleeding and liver failure worsens the prognosis. In such cases, liver transplantation is considered.
Newborn screening and early intervention: when CF is diagnosed early by newborn screening, EPI can be identified early and PERT started to prevent nutritional deficiency. The short-term prognosis of meconium ileus also improves greatly when it is treated immediately in the neonatal period.
Early use of CFTR modulators: early administration of ELX/TEZ/IVA in eligible patients aged 2 years or older is expected to normalize intestinal mucus secretion and help prevent worsening of EPI and the development of DIOS.
Prevention of DIOS: in patients with CF, adequate fluid intake (at least 2L or more per day, more with exercise), regular exercise to maintain bowel motility, continued and optimized PERT, adjustment of dietary fiber and prompt treatment of constipation are important. In patients with previous DIOS, preventive PEG (macrogol) is effective in preventing recurrence.
Genetic counseling: carrier testing and genetic counseling for the parents and family of patients with CF make them aware of the recurrence risk and prepare for prenatal care.
Vaccination: vaccinations to prevent gastrointestinal infections (rotavirus, hepatitis A and B, typhoid fever, etc.) are kept up to date. Vaccination is recommended because even CF patients without immunodeficiency are vulnerable to recurrent infections.